go coogs

University of Houston scores national award for championing diversity

UH has been recognized for its excellence in diversity. Photo courtesy of University of Houston

Fresh off news of a new free health clinic for the homeless, the University of Houston is once again making headlines for its commitment to empowering the community. INSIGHT Into Diversity magazine has announced UH and the University of Houston Law Center as recipients of its 2021 Higher Education Excellence in Diversity (HEED) Award.

This is the sixth consecutive year UH and the law center has received the award. UH's law center was also named a Diversity Champion — the only law school to receive that honor. The magazine is recognized as the oldest and largest diversity-focused publication in higher education in the U.S.

INSIGHT Into Diversity's award recognizes U.S. colleges and universities that demonstrate an outstanding commitment to diversity and inclusion, according to a press release.

To score this honor, schools must undergo a comprehensive and rigorous application process that includes questions relating to the recruitment and retention of students and employees — and best practices for both — continued leadership support for diversity, per a release. Other aspects of campus diversity and inclusion are also scrutinized.

UH's law center, the sole Diversity Champion winner, was heralded by the publication for its "unyielding commitment to diversity and inclusion throughout their campus communities, across academic programs, and at the highest administrative levels."

"The Law Center's mission has always been clear," said Leonard Baynes, dean of the UH Law Center, in a statement. "We have historically provided opportunities for many first-generation college students. Our faculty teach students to be successful lawyers and have confidence in themselves despite societal barriers."

Fans, alums, and students can look for UH and its law center to be featured, along with 100 other recipients, in the November 2021 issue of INSIGHT Into Diversity.

------

This article originally ran on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted